Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr joins Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial.
Lehr says two patients have achieved a confirmed partial response among the first 12 patients enrolled in its Phase 2 OATH clinical trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone-receptor positive metastatic endometrial cancer. Lehr adds that the findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage.